Neurology® Podcast cover image

Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine

Neurology® Podcast

00:00

The FDA Shouldn't Approve Aticanama Ut

The fda should not have approved aducana mab, and yet i will prescribe y mab, but reluctantly. I am one among those physicians who disagree with this decision. And so yes, if after someone learns all about this very complicated drug, and they fit the criteria for it, you know, i am a reluctant prescriber out of that respect for their individual autonomy.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app